<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03707041</url>
  </required_header>
  <id_info>
    <org_study_id>MMV_P218_17_01</org_study_id>
    <secondary_id>2018-003004-39</secondary_id>
    <nct_id>NCT03707041</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model</brief_title>
  <official_title>A Single Centre, Randomised, Double-blind, Placebo-controlled, Phase Ib Study to Evaluate the Safety, Tolerability and Chemoprotective Antimalarial Activity of P218 Against Controlled Human Malaria Infection With Plasmodium Falciparum Sporozoite Challenge in Non-immune Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SGS Life Sciences, a division of SGS Belgium NV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss BioQuant A.G., Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PrimeVigilance Ltd., UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biologic LLP, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanaria Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>FGK Representative Service B.V., The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a single centre, randomised, double-blind, placebo-controlled Phase Ib study, to&#xD;
      evaluate the safety, tolerability and chemoprotective activity of P218 in a controlled P.&#xD;
      falciparum sporozoite infection model.&#xD;
&#xD;
      Healthy men and women, aged 18 to 45 years were to be enrolled in 3 study cohorts and to be&#xD;
      administered either P218 or placebo twice, 48 hours apart. Subjects in cohorts 2 and 3 were&#xD;
      to be inoculated with P. falciparum sporozoites. Enrolment in cohorts was to proceed&#xD;
      sequentially, to facilitate review of data by a Safety Review Team (SRT) before proceeding&#xD;
      with a subsequent cohort.&#xD;
&#xD;
      In cohort 1, safety and tolerability of P218 was assessed. In cohorts 2 and 3,&#xD;
      chemoprotective activity of P218 against malaria infection was assessed, as well as the&#xD;
      Influence of time of initiation of the P218 treatment on the protective effect.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a single centre, randomised, double-blind, placebo-controlled Phase Ib study, to&#xD;
      evaluate the safety, tolerability and chemoprotective activity of P218 in a controlled P.&#xD;
      falciparum sporozoite infection model.&#xD;
&#xD;
      32 healthy men and women, aged 18 to 45 years were to be enrolled in 3 cohorts of&#xD;
      respectively 8, 12 and 12 subjects. A subject could be enrolled in one cohort only and was to&#xD;
      be randomised in a 3:1 ratio, to receive two consecutive administrations, 48 hours apart, of&#xD;
      either P218 or placebo. Enrolment in cohorts proceeded sequentially, to facilitate review of&#xD;
      data by a Safety Review Team (SRT) before populating a subsequent cohort.&#xD;
&#xD;
      Cohort 1 consisted of 2 subgroups of subjects, to be enrolled sequentially: subgroup 1 was to&#xD;
      be composed of 2 subjects: one to receive two 1000 mg doses of P218 and one to receive&#xD;
      placebo twice. Subgroup 2 was to be composed of 6 subjects: five to receive two 1000 mg doses&#xD;
      of P218 and one to receive placebo twice. Subjects in subgroup 2 would not be treated until&#xD;
      24 hours after second IMP administration in the last subject of subgroup 1 and only after&#xD;
      review of the safety data from subgroup 1 by the PI. Duration of each subject treatment and&#xD;
      follow-up in Cohort 1 was 9 days. Progression to Cohort 2 was subject to review of the safety&#xD;
      and tolerability data by a SRT.&#xD;
&#xD;
      Cohort 2 consisted of three subgroups of subjects, to be enrolled sequentially. Subgroup 1&#xD;
      was to be composed of 2 subjects: one to receive two 1000 mg doses of P218 and one to receive&#xD;
      placebo twice. Subgroups 2 and 3 were to be composed of 5 subjects each: four to receive two&#xD;
      1000 mg doses of P218 and one to receive placebo twice. Subjects in subgroup 2 would not be&#xD;
      treated until 24 hours after second IMP administration in the last subject of subgroup 1. On&#xD;
      Day 1, each subject in Cohort 2 would be administered 3200 P. falciparum sporozoites (PfSPZ&#xD;
      Challenge) by direct venous inoculation (DVI). First administration of 1000 mg of P218 or&#xD;
      placebo will take place 2 hours after PfSPZ Challenge DVI; second administration of 1000 mg&#xD;
      of P218 or placebo would take place 48 hours later. As of Day 7, parasitemia in every subject&#xD;
      was to be assessed daily until the installation of malarial infection or until Day 28.&#xD;
      Overall duration of each subject observation in Cohort 2 was 35 days. Progression to Cohort 3&#xD;
      was subject to assessment of safety and parasitemia data, as well as malaria signs and&#xD;
      symptoms by a SRT.&#xD;
&#xD;
      Cohort 3 was to consist of two subgroups each with 6 subjects, to be enrolled sequentially.&#xD;
      Treatment was to be allocated in a ratio of 3 active: 1 placebo. In each subgroup, at least 1&#xD;
      subject was to receive placebo and the remaining subjects would receive two 100 mg doses of&#xD;
      P218 48 hours apart. Subjects in subgroup 2 would not be inoculated until 24 hours after&#xD;
      second IMP administration in the last subject of subgroup 1. On Day 1, subjects were to be&#xD;
      administered 3200 P. falciparum sporozoites by DVI. As of Day 7, parasitemia in every subject&#xD;
      was to be assessed daily until the installation of malarial infection or until Day 28.&#xD;
      Overall duration of each subject observation in Cohort 3 is 35 days.&#xD;
&#xD;
      All subjects in Cohorts 2 and 3 would receive antimalarial rescue therapy, either upon&#xD;
      installation of malarial infection or on Day 28 or if leaving the study prematurely.&#xD;
&#xD;
      In Cohort 1, safety and tolerability of two 1000 mg doses of P218 administered 48 hours apart&#xD;
      was to be assessed over 9 days of observation. Pharmacokinetic assessments of P218 and its&#xD;
      main metabolites were to take place over 9 days of observation.&#xD;
&#xD;
      In Cohorts 2 and 3, chemoprotective activity of two doses P218 (1000 mg or 100 mg&#xD;
      respectively) administered 48 hours apart, were to be assessed over 28 days. Safety and&#xD;
      tolerability of two doses of P218 (1000 mg or 100 mg respectively) administered 48 hours&#xD;
      apart were to be assessed over 35 days of observation. Pharmacokinetic assessments of P218&#xD;
      would take place over 9 days of observation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2018</start_date>
  <completion_date type="Actual">June 3, 2019</completion_date>
  <primary_completion_date type="Actual">May 27, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In each of the three treatment cohorts, subjects will be randomly allocated to receive either P218 or placebo.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo capsules matched to the drug product with regard to appearance and taste</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort 1: Number of TEAEs</measure>
    <time_frame>9 days</time_frame>
    <description>Incidence, severity and relationship to the treatment of observed or self-reported treatment emergent adverse events (TEAEs) after two single doses of 1000 mg P218 administered 48 hours apart in healthy adult volunteers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohorts 2 and 3: Geometric Mean Time From PfSPZ Challenge to First Quantitative Polymerase Chain Reaction (qPCR) Outcome Equal or Greater Than 250 Asexual Parasites Per mL of Blood</measure>
    <time_frame>Number of days from PfSPZ Challenge DVI to positive parasitaemia, or 28 days</time_frame>
    <description>Chemoprotective activity of two single doses of 1000 mg P218 administered 2 hours after PfSPZ Challenge and 48 hours later in healthy adult volunteers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohorts 2 and 3: Number of P218 TEAEs</measure>
    <time_frame>35 days</time_frame>
    <description>Incidence, severity and relationship to the P218 treatment of observed or self-reported treatment emergent adverse events in non-immune healthy adult volunteers after two single doses of 1000 mg P218 administered 48 hours apart in a controlled human malaria infection (PfSPZ Challenge)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts 2 and 3: Number of PfSPZ Challenge TEAEs</measure>
    <time_frame>35 days</time_frame>
    <description>Incidence, severity and relationship to the PfSPZ Challenge of observed or self-reported treatment emergent adverse events in non-immune healthy adult volunteers before and after P218 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts 2 and 3: Malaria Clinical Score at the Time of Introduction of Rescue Therapy</measure>
    <time_frame>On the day of positive parasitaemia or on Day 28</time_frame>
    <description>The malaria clinical score consists of 14 signs/symptoms frequently associated with malaria and graded using a 4-point scale (absent: 0; mild: 1; moderate: 2; severe: 3) and summed to generate a total malaria clinical score (maximum score possible is 42): headache, myalgia (muscle ache), arthralgia (joint ache), fatigue/lethargy, malaise (general discomfort/uneasiness), chills/shivering/rigors, sweating/hot spells, anorexia, nausea, vomiting, abdominal discomfort, fever, tachycardia and hypotension.&#xD;
To determine severity of the 14 signs/symptoms the CTCAE grading scale grade 1 - 5 was used. Mild (1) equates to CTCAE grade 1, Moderate (2) equates to CTCAE grade 2 and Severe (3) equates to CTCAE grade 3 or above. Individual scores for each symptom as well as the total score were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts 1, 2 and 3: P218 AUC[0-48h] - Day 1</measure>
    <time_frame>9 days</time_frame>
    <description>Area under the P218 plasma concentration-time curve from first administration to 48 hours after first administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: P218-beta-acyl-glucuronide-OH AUC[48-96h]</measure>
    <time_frame>9 days</time_frame>
    <description>Area under the P218-beta-acyl-glucuronide-OH plasma concentration-time curve from 48 hours after first P218 administration to 96 hours after first P218 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts 1, 2 and 3: P218 Cmax - Day 1</measure>
    <time_frame>9 days</time_frame>
    <description>Maximum observed P218 plasma concentration after each P218 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohorts 1, 2 and 3: P218 Tmax - Day 1</measure>
    <time_frame>9 days</time_frame>
    <description>Time to P218 Cmax after each P218 administration</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>P218 1000 mg (Oral Capsules) - Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two administrations of 1000 mg P218 (capsules p.o.), 48 hours apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P218 Placebo Oral Capsules - Cohort 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two administrations of P218 placebo (capsules p.o.), 48 hours apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P218 1000 mg (Oral Capsules) - Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P218 Placebo Oral Capsules - Cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.,) 48 hours after first administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P218 100 mg (Oral Capsules) - Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P218 Placebo Oral Capsule - Cohort 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.), 48 hours after first administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P218 (1000 mg) Oral Capsules</intervention_name>
    <description>1000 mg P218 (4 x 250 mg capsules)</description>
    <arm_group_label>P218 1000 mg (Oral Capsules) - Cohort 1</arm_group_label>
    <arm_group_label>P218 1000 mg (Oral Capsules) - Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Capsules</intervention_name>
    <description>Placebo capsules matched to the P218 capsules with regard to appearance and taste</description>
    <arm_group_label>P218 Placebo Oral Capsule - Cohort 3</arm_group_label>
    <arm_group_label>P218 Placebo Oral Capsules - Cohort 1</arm_group_label>
    <arm_group_label>P218 Placebo Oral Capsules - Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P218 (100 mg) Oral Capsules</intervention_name>
    <description>100 mg P218 (2 x 50 mg capsules)</description>
    <arm_group_label>P218 100 mg (Oral Capsules) - Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PfSPZ Challenge</intervention_name>
    <description>3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
    <arm_group_label>P218 100 mg (Oral Capsules) - Cohort 3</arm_group_label>
    <arm_group_label>P218 1000 mg (Oral Capsules) - Cohort 2</arm_group_label>
    <arm_group_label>P218 Placebo Oral Capsule - Cohort 3</arm_group_label>
    <arm_group_label>P218 Placebo Oral Capsules - Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subjects meeting all of the following criteria are eligible to participate in this study:&#xD;
&#xD;
          1. Informed Consent Form signed voluntarily before any study-related procedure is&#xD;
             performed, indicating that the subject understands the purpose of and procedures&#xD;
             required for the study and is willing to participate in the study, including&#xD;
             administration of rescue treatment.&#xD;
&#xD;
          2. Male or female, between 18 and 45 years old (extremes included) at screening.&#xD;
&#xD;
          3. Body weight of at least 50 kg and a body mass index (BMI) of 19 to 30 kg/m2 (extremes&#xD;
             included).&#xD;
&#xD;
          4. Good general health without clinically relevant medical illness, physical exam&#xD;
             findings including vital signs, and laboratory abnormalities as determined by the&#xD;
             investigator.&#xD;
&#xD;
          5. Willing to adhere to the prohibitions and restrictions (see Section 4.3) specified in&#xD;
             this protocol, including willingness to stay confined to the inpatient unit for&#xD;
             required duration and willingness to avoid to travel outside of Benelux during the&#xD;
             study period.&#xD;
&#xD;
          6. Female subjects should fulfil one of the following criteria:&#xD;
&#xD;
               1. At least 1 year post-menopausal (amenorrhea &gt;12 months and follicle-stimulating&#xD;
                  hormone (FSH) &gt;30 mIU/mL) prior to screening;&#xD;
&#xD;
               2. Surgically sterile (bilateral oophorectomy, hysterectomy or tubal ligation);&#xD;
&#xD;
               3. Will use contraceptives as outlined in inclusion criteria 7 and 8.&#xD;
&#xD;
          7. Female subjects of childbearing potential must agree to the use of a highly effective&#xD;
             method of birth control from screening visit to until 40 days after the last dose of&#xD;
             IMP (covering a full menstrual cycle of 30 days starting after 5 half-lives of last&#xD;
             dose of IMP).&#xD;
&#xD;
             Note: Highly effective birth control methods include: combined (estrogen and&#xD;
             progestogen containing) oral/intravaginal/transdermal hormonal contraception&#xD;
             associated with inhibition of ovulation, progestogen-only oral/injectable/implantable&#xD;
             hormonal contraception associated with inhibition of ovulation, intrauterine device,&#xD;
             intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner&#xD;
             or sexual abstinence.&#xD;
&#xD;
          8. Male subjects who are sexually active with a female partner of childbearing potential&#xD;
             must agree to the use of an effective method of birth control from the day of the&#xD;
             first IMP dose until 100 days thereafter (covering a full sperm cycle of 90 days&#xD;
             starting after 5 half-lives of last dose of IMP).&#xD;
&#xD;
             Note: Medically acceptable methods of contraception that may be used by the subject&#xD;
             and/or partner include sterilization and vasectomy or a double barrier option&#xD;
             combining oral contraceptive, contraceptive vaginal ring, contraceptive injection,&#xD;
             intrauterine device or etonogestrel implant.&#xD;
&#xD;
          9. Female subject has a negative pregnancy test at screening and upon admission in the&#xD;
             clinical unit.&#xD;
&#xD;
             Note: Pregnancy testing will consist of a serum β-human chorionic gonadotropin (β-HCG)&#xD;
             test at screening and urine β-HCG tests at other visits, in all women.&#xD;
&#xD;
             Inclusion Criteria - CHMI (controlled human malaria infection) specific:&#xD;
&#xD;
         10. Different ways of being reachable 24/7 (e.g. by mobile phone, regular phone or&#xD;
             electronic mail) during the whole study period.&#xD;
&#xD;
        Subjects meeting any of the following criteria are excluded from participation in this&#xD;
        study:&#xD;
&#xD;
          1. Nursing (lactating) women.&#xD;
&#xD;
          2. Participation in any other clinical drug or vaccine study within 30 days (or five&#xD;
             half-lives for drugs) preceding the first dose of IMP (whichever is longer), or plans&#xD;
             to participate in other investigational drug or vaccine research during the study&#xD;
             period.&#xD;
&#xD;
          3. Blood product donation to any blood bank during the 8 weeks (whole blood) or 4 weeks&#xD;
             (plasma and platelets) prior to admission in the clinical unit.&#xD;
&#xD;
          4. ECG outside normal range and deemed clinically relevant by the investigator. Examples&#xD;
             of clinically significant ECG abnormalities for this study include:&#xD;
&#xD;
               1. PR-interval &gt;220 ms;&#xD;
&#xD;
               2. QRS-complex &gt;120 ms;&#xD;
&#xD;
               3. QT interval corrected according to Bazett's formula (QTcB) or QT interval&#xD;
                  corrected according to Fridericia's formula [3] (QTcF) &gt;450 ms;&#xD;
&#xD;
               4. Pathologic Q wave;&#xD;
&#xD;
               5. Significant ST-T wave changes;&#xD;
&#xD;
               6. Left or right ventricular hypertrophy;&#xD;
&#xD;
               7. Non-sinus rhythm except isolated premature atrial contractions and ventricular&#xD;
                  extrasystole &lt;2 per 10 s ECG lead;&#xD;
&#xD;
               8. Incomplete left bundle branch block, or complete or intermittent right or left&#xD;
                  bundle branch block;&#xD;
&#xD;
               9. Second or third degree A-V heart block.&#xD;
&#xD;
          5. Seropositive human immunodeficiency virus (HIV) (antibody and antigen), hepatitis B&#xD;
             virus (HBV) (hepatitis B surface antigen [HBsAg]) or hepatitis C virus (HCV)&#xD;
             (antibody) tests.&#xD;
&#xD;
          6. History or presence of diagnosed food or known drug allergies (including but not&#xD;
             limited to allergy to any of the antimalarial rescue medications to be used in the&#xD;
             study, see Section 5.2), or history of anaphylaxis or other severe allergic reactions.&#xD;
&#xD;
             Note: Subjects with seasonal allergies/hay fever, house dust mite or allergy to&#xD;
             animals that are untreated and asymptomatic at the time of dosing can be enrolled in&#xD;
             the study.&#xD;
&#xD;
          7. History of convulsion or severe head trauma.&#xD;
&#xD;
             Note: A medical history of a single febrile convulsion during childhood is not an&#xD;
             exclusion criteria.&#xD;
&#xD;
          8. History of serious psychiatric condition that may affect participation in the study or&#xD;
             preclude compliance with the protocol, including but not limited to past or present&#xD;
             psychoses, disorders requiring lithium, a history of attempted or planned suicide,&#xD;
             more than one previous episode of major depression, any previous single episode of&#xD;
             major depression lasting for or requiring treatment for more than 6 months, or any&#xD;
             episode of major depression during the 5 years preceding screening.&#xD;
&#xD;
             Note: The Beck Depression Inventory (Attachment 2) will be used as an objective tool&#xD;
             for the assessment of depression at screening. In addition to the conditions listed&#xD;
             above, subjects with a score of 20 or more on the Beck Depression Inventory and/or a&#xD;
             response of 1, 2 or 3 for item 9 of this inventory (related to suicidal ideation) will&#xD;
             not be eligible for participation. Subjects with a Beck score of 17 to 19 may be&#xD;
             enrolled at the discretion of the Investigator if they do not have a history of the&#xD;
             psychiatric conditions mentioned in this criterion and their mental state is not&#xD;
             considered to pose additional risk to the health of the volunteer or to the execution&#xD;
             of the study and interpretation of the data gathered.&#xD;
&#xD;
          9. A medical, occupational or family problem as a result of alcohol or illicit drug abuse&#xD;
             during the past 12 months or current alcohol or illicit drug abuse or addiction&#xD;
             (positive alcohol breath test or positive drug screen for amphetamines, barbiturates,&#xD;
             benzodiazepines, cannabinoids, cocaine or opiates at screening or upon check-in at the&#xD;
             clinical unit).&#xD;
&#xD;
             Note: Excessive use of alcohol is an intake of &gt;21 units per week for males and &gt;14&#xD;
             units per week for females where one alcohol unit is defined as 10 mL or 8 g of pure&#xD;
             alcohol. A single unit is equal to one 25-mL (single) measure of whisky (alcohol by&#xD;
             volume [ABV] 40%), or a third of a pint of beer (190 mL; ABV 5-6%) or half a standard&#xD;
             (175 mL) glass of wine (ABV 12%).&#xD;
&#xD;
         10. Subjects are non-smokers or ex-smokers for more than 90 days prior to screening or&#xD;
             smoke no more than 5 cigarettes per day. If users of nicotine products (i.e. spray,&#xD;
             patch, e-cigarette, etc.) they should use the equivalent of no more than 5 cigarettes&#xD;
             per day. Subjects must agree to abstain from smoking while in the unit.&#xD;
&#xD;
         11. Use of any prescription drugs, herbal supplements (e.g. St John's Wort) or&#xD;
             over-the-counter medication within 7 days or five half-lives (whichever is longer)&#xD;
             prior to the first IMP administration, or an anticipated requirement for the use of&#xD;
             these during the course of the study (See Section 6.2).&#xD;
&#xD;
             Note: If necessary, the incidental use of non-steroidal anti-inflammatory drugs&#xD;
             (NSAIDs), paracetamol (2g/day, 10 gr/week), vitamins and topical treatments may be&#xD;
             acceptable after approval by the study Sponsor and will be documented in the eSource&#xD;
             system. The use of nutritional supplements during this time that are not believed to&#xD;
             have the potential to affect subject safety nor the overall results of the study, may&#xD;
             be permitted on a case-by-case basis following approval by the Sponsor in consultation&#xD;
             with the Investigator.&#xD;
&#xD;
         12. Any surgical or medical condition possibly affecting drug absorption (e.g.&#xD;
             cholecystectomy, gastrectomy, bowel disease), distribution, metabolism or excretion.&#xD;
&#xD;
         13. Any history of gallbladder disease, including cholecystitis and/or cholelithiasis.&#xD;
&#xD;
         14. History of megaloblastic anaemia or folate deficiency.&#xD;
&#xD;
         15. Personnel (e.g. investigator, sub-investigator, research assistant, pharmacist, study&#xD;
             coordinator or anyone mentioned in the delegation log) directly involved in the&#xD;
             conduct of the study.&#xD;
&#xD;
         16. Any condition that in the opinion of the investigator would jeopardize the safety or&#xD;
             rights of a person participating in the trial or would render the person unable to&#xD;
             comply with the protocol.&#xD;
&#xD;
             Exclusion Criteria - CHMI specific:&#xD;
&#xD;
         17. Glucose-6-phosphate dehydrogenase (G6PD) deficiency (due to possible hemolysis induced&#xD;
             by primaquine treatment at study end in G6PD deficient subjects).&#xD;
&#xD;
         18. Personal history of malaria.&#xD;
&#xD;
         19. Volunteer has travelled to or lived in a malaria-endemic area for more than 4 weeks&#xD;
             during the 12 months prior to first IMP administration, or spent any time in an&#xD;
             endemic area during the 4 weeks prior to first IMP administration.&#xD;
&#xD;
         20. Plans to travel to malaria-endemic region during the study period up to last follow-up&#xD;
             visit.&#xD;
&#xD;
         21. Previous participation in any malaria vaccine or CHMI study.&#xD;
&#xD;
         22. Falling in moderate or higher risk category for a fatal or non-fatal cardiovascular&#xD;
             event within 10 years (≥5%) determined by a validated risk estimation system e.g.&#xD;
             SCORE [13].&#xD;
&#xD;
         23. Use of medications known to interact with atovaquone-proguanil (Malarone®),&#xD;
             artemether-lumefantrine (Riamet®) or primaquine (Primaquine®) such as cimetidine,&#xD;
             metoclopramide or antacids, or an anticipated requirement for the use of these at any&#xD;
             point during the study period (see Section 6.2).&#xD;
&#xD;
         24. Use of systemic antibiotics with known antimalarial activity within 30 days (or 5&#xD;
             half-lives whichever is longer) of first IMP administration (e.g.&#xD;
             trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin,&#xD;
             fluoroquinolones or azithromycin) or an anticipated requirement for the use of these&#xD;
             during the study period (see Section 6.2).&#xD;
&#xD;
         25. Receipt of blood or blood-derived products (including immunoglobulin) within 3 months&#xD;
             prior to screening. Receipt of packed red blood cells given for an emergent indication&#xD;
             in an otherwise healthy person, and not required as ongoing treatment is not&#xD;
             exclusionary (for example packed red blood cells emergently given during an elective&#xD;
             surgery).&#xD;
&#xD;
        Note: In case of an out-of-range clinical laboratory test, vital sign or ECG value that&#xD;
        will determine a subject's eligibility, or in case of a positive drug screen, a retest or&#xD;
        expert evaluation can be requested. Results of any retest must be available prior to&#xD;
        inoculation. The result of the retest will be considered for subject eligibility at the&#xD;
        investigator's discretion. Subjects can be rescreened at the discretion of the&#xD;
        investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Donini, PhD</last_name>
    <role>Study Director</role>
    <affiliation>MMV</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pieter-Jan Berghmans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGS Belgium NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Belgium NV Clinical Pharmacology Unit</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2018</study_first_posted>
  <results_first_submitted>February 11, 2020</results_first_submitted>
  <results_first_submitted_qc>March 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2021</results_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malaria</keyword>
  <keyword>PfSPZ Challenge</keyword>
  <keyword>chemoprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT03707041/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT03707041/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at the SGS Life Sciences Clinical Pharmacology Unit in Antwerp.</recruitment_details>
      <pre_assignment_details>61 subjects were screened, 32 subjects were enrolled and randomised.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>P218 1000 mg (Oral Capsules) - Cohort 1</title>
          <description>Two administrations of 1000 mg P218 (capsules p.o.), 48 hours apart&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)</description>
        </group>
        <group group_id="P2">
          <title>P218 Placebo Oral Capsules - Cohort 1</title>
          <description>Two administrations of P218 placebo (capsules p.o.), 48 hours apart&#xD;
Placebo Oral Capsules: Placebo capsules matched to the P218 capsules with regard to appearance and taste</description>
        </group>
        <group group_id="P3">
          <title>P218 1000 mg (Oral Capsules) - Cohort 2</title>
          <description>One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
        </group>
        <group group_id="P4">
          <title>P218 Placebo Oral Capsules - Cohort 2</title>
          <description>One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.,) 48 hours after first administration.&#xD;
Placebo Oral Capsules: Placebo capsules matched to the P218 capsules with regard to appearance and taste&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
        </group>
        <group group_id="P5">
          <title>P218 100 mg (Oral Capsules) - Cohort 3</title>
          <description>One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (100 mg) Oral Capsules: 100 mg P218 (2 x 50 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
        </group>
        <group group_id="P6">
          <title>P218 Placebo Oral Capsule - Cohort 3</title>
          <description>One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.), 48 hours after first administration.&#xD;
Placebo Oral Capsules: Placebo capsules matched to the P218 capsules with regard to appearance and taste&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>P218 1000 mg (Oral Capsules) - Cohort 1</title>
          <description>Two administrations of 1000 mg P218 (capsules p.o.), 48 hours apart&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)</description>
        </group>
        <group group_id="B2">
          <title>P218 Placebo Oral Capsules - Cohort 1</title>
          <description>Two administrations of P218 placebo (capsules p.o.), 48 hours apart&#xD;
Placebo Oral Capsules: Placebo capsules matched to the P218 capsules with regard to appearance and taste</description>
        </group>
        <group group_id="B3">
          <title>P218 1000 mg (Oral Capsules) - Cohort 2</title>
          <description>One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
        </group>
        <group group_id="B4">
          <title>P218 100 mg (Oral Capsules) - Cohort 3</title>
          <description>One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (100 mg) Oral Capsules: 100 mg P218 (2 x 50 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
        </group>
        <group group_id="B5">
          <title>P218 Placebo Oral Capsule - Cohorts 2 and 3</title>
          <description>One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.), 48 hours after first administration.&#xD;
Placebo Oral Capsules: Placebo capsules matched to the P218 capsules with regard to appearance and taste&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" lower_limit="24" upper_limit="45"/>
                    <measurement group_id="B2" value="24.5" lower_limit="24" upper_limit="25"/>
                    <measurement group_id="B3" value="36.0" lower_limit="22" upper_limit="40"/>
                    <measurement group_id="B4" value="35.0" lower_limit="23" upper_limit="42"/>
                    <measurement group_id="B5" value="34.5" lower_limit="33" upper_limit="42"/>
                    <measurement group_id="B6" value="29.5" lower_limit="22" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cohort 1: Number of TEAEs</title>
        <description>Incidence, severity and relationship to the treatment of observed or self-reported treatment emergent adverse events (TEAEs) after two single doses of 1000 mg P218 administered 48 hours apart in healthy adult volunteers.</description>
        <time_frame>9 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P218 1000 mg (Oral Capsules) - Cohort 1</title>
            <description>Two administrations of 1000 mg P218 (capsules p.o.), 48 hours apart&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)</description>
          </group>
          <group group_id="O2">
            <title>P218 Placebo Oral Capsules - Cohort 1</title>
            <description>Two administrations of P218 placebo (capsules p.o.), 48 hours apart&#xD;
Placebo Oral Capsules: Placebo capsules matched to the P218 capsules with regard to appearance and taste</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Number of TEAEs</title>
          <description>Incidence, severity and relationship to the treatment of observed or self-reported treatment emergent adverse events (TEAEs) after two single doses of 1000 mg P218 administered 48 hours apart in healthy adult volunteers.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Subjects with any TEAE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subjects without any TEAE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohorts 2 and 3: Geometric Mean Time From PfSPZ Challenge to First Quantitative Polymerase Chain Reaction (qPCR) Outcome Equal or Greater Than 250 Asexual Parasites Per mL of Blood</title>
        <description>Chemoprotective activity of two single doses of 1000 mg P218 administered 2 hours after PfSPZ Challenge and 48 hours later in healthy adult volunteers</description>
        <time_frame>Number of days from PfSPZ Challenge DVI to positive parasitaemia, or 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P218 1000 mg (Oral Capsules) - Cohort 2</title>
            <description>One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
          <group group_id="O2">
            <title>P218 100 mg (Oral Capsules) - Cohort 3</title>
            <description>One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (100 mg) Oral Capsules: 100 mg P218 (2 x 50 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
          <group group_id="O3">
            <title>P218 Placebo Oral Capsule - Cohorts 2 and 3</title>
            <description>One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.), 48 hours after first administration.&#xD;
Placebo Oral Capsules: Placebo capsules matched to the P218 capsules with regard to appearance and taste&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
        </group_list>
        <measure>
          <title>Cohorts 2 and 3: Geometric Mean Time From PfSPZ Challenge to First Quantitative Polymerase Chain Reaction (qPCR) Outcome Equal or Greater Than 250 Asexual Parasites Per mL of Blood</title>
          <description>Chemoprotective activity of two single doses of 1000 mg P218 administered 2 hours after PfSPZ Challenge and 48 hours later in healthy adult volunteers</description>
          <units>Days</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.000" lower_limit="28.000" upper_limit="28.000"/>
                    <measurement group_id="O2" value="25.822" lower_limit="22.396" upper_limit="29.771"/>
                    <measurement group_id="O3" value="10.615" lower_limit="9.918" upper_limit="11.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohorts 2 and 3: Number of P218 TEAEs</title>
        <description>Incidence, severity and relationship to the P218 treatment of observed or self-reported treatment emergent adverse events in non-immune healthy adult volunteers after two single doses of 1000 mg P218 administered 48 hours apart in a controlled human malaria infection (PfSPZ Challenge)</description>
        <time_frame>35 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P218 1000 mg (Oral Capsules) - Cohort 2</title>
            <description>One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
          <group group_id="O2">
            <title>P218 100 mg (Oral Capsules) - Cohort 3</title>
            <description>One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (100 mg) Oral Capsules: 100 mg P218 (2 x 50 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
          <group group_id="O3">
            <title>P218 Placebo Oral Capsule - Cohorts 2 and 3</title>
            <description>One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.), 48 hours after first administration.&#xD;
Placebo Oral Capsules: Placebo capsules matched to the P218 capsules with regard to appearance and taste&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
        </group_list>
        <measure>
          <title>Cohorts 2 and 3: Number of P218 TEAEs</title>
          <description>Incidence, severity and relationship to the P218 treatment of observed or self-reported treatment emergent adverse events in non-immune healthy adult volunteers after two single doses of 1000 mg P218 administered 48 hours apart in a controlled human malaria infection (PfSPZ Challenge)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any P218-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No P218-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohorts 2 and 3: Number of PfSPZ Challenge TEAEs</title>
        <description>Incidence, severity and relationship to the PfSPZ Challenge of observed or self-reported treatment emergent adverse events in non-immune healthy adult volunteers before and after P218 administration</description>
        <time_frame>35 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P218 1000 mg (Oral Capsules) - Cohort 2</title>
            <description>One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
          <group group_id="O2">
            <title>P218 100 mg (Oral Capsules) - Cohort 3</title>
            <description>One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (100 mg) Oral Capsules: 100 mg P218 (2 x 50 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
          <group group_id="O3">
            <title>P218 Placebo Oral Capsule - Cohorts 2 and 3</title>
            <description>One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.), 48 hours after first administration.&#xD;
Placebo Oral Capsules: Placebo capsules matched to the P218 capsules with regard to appearance and taste&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
        </group_list>
        <measure>
          <title>Cohorts 2 and 3: Number of PfSPZ Challenge TEAEs</title>
          <description>Incidence, severity and relationship to the PfSPZ Challenge of observed or self-reported treatment emergent adverse events in non-immune healthy adult volunteers before and after P218 administration</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Subjects with any TEAE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subjects without any TEAE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohorts 2 and 3: Malaria Clinical Score at the Time of Introduction of Rescue Therapy</title>
        <description>The malaria clinical score consists of 14 signs/symptoms frequently associated with malaria and graded using a 4-point scale (absent: 0; mild: 1; moderate: 2; severe: 3) and summed to generate a total malaria clinical score (maximum score possible is 42): headache, myalgia (muscle ache), arthralgia (joint ache), fatigue/lethargy, malaise (general discomfort/uneasiness), chills/shivering/rigors, sweating/hot spells, anorexia, nausea, vomiting, abdominal discomfort, fever, tachycardia and hypotension.&#xD;
To determine severity of the 14 signs/symptoms the CTCAE grading scale grade 1 - 5 was used. Mild (1) equates to CTCAE grade 1, Moderate (2) equates to CTCAE grade 2 and Severe (3) equates to CTCAE grade 3 or above. Individual scores for each symptom as well as the total score were recorded.</description>
        <time_frame>On the day of positive parasitaemia or on Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P218 1000 mg (Oral Capsules) - Cohort 2</title>
            <description>One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
          <group group_id="O2">
            <title>P218 100 mg (Oral Capsules) - Cohort 3</title>
            <description>One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (100 mg) Oral Capsules: 100 mg P218 (2 x 50 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
          <group group_id="O3">
            <title>P218 Placebo Oral Capsule - Cohorts 2 and 3</title>
            <description>One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.), 48 hours after first administration.&#xD;
Placebo Oral Capsules: Placebo capsules matched to the P218 capsules with regard to appearance and taste&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
        </group_list>
        <measure>
          <title>Cohorts 2 and 3: Malaria Clinical Score at the Time of Introduction of Rescue Therapy</title>
          <description>The malaria clinical score consists of 14 signs/symptoms frequently associated with malaria and graded using a 4-point scale (absent: 0; mild: 1; moderate: 2; severe: 3) and summed to generate a total malaria clinical score (maximum score possible is 42): headache, myalgia (muscle ache), arthralgia (joint ache), fatigue/lethargy, malaise (general discomfort/uneasiness), chills/shivering/rigors, sweating/hot spells, anorexia, nausea, vomiting, abdominal discomfort, fever, tachycardia and hypotension.&#xD;
To determine severity of the 14 signs/symptoms the CTCAE grading scale grade 1 - 5 was used. Mild (1) equates to CTCAE grade 1, Moderate (2) equates to CTCAE grade 2 and Severe (3) equates to CTCAE grade 3 or above. Individual scores for each symptom as well as the total score were recorded.</description>
          <units>Malaria Clinical Score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohorts 1, 2 and 3: P218 AUC[0-48h] - Day 1</title>
        <description>Area under the P218 plasma concentration-time curve from first administration to 48 hours after first administration</description>
        <time_frame>9 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P218 1000 mg (Oral Capsules) - Cohort 1</title>
            <description>Two administrations of 1000 mg P218 (capsules p.o.), 48 hours apart&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)</description>
          </group>
          <group group_id="O2">
            <title>P218 1000 mg (Oral Capsules) - Cohort 2</title>
            <description>One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
          <group group_id="O3">
            <title>P218 100 mg (Oral Capsules) - Cohort 3</title>
            <description>One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (100 mg) Oral Capsules: 100 mg P218 (2 x 50 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
        </group_list>
        <measure>
          <title>Cohorts 1, 2 and 3: P218 AUC[0-48h] - Day 1</title>
          <description>Area under the P218 plasma concentration-time curve from first administration to 48 hours after first administration</description>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16752" spread="6958"/>
                    <measurement group_id="O2" value="13865" spread="2663"/>
                    <measurement group_id="O3" value="1296" spread="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 1: P218-beta-acyl-glucuronide-OH AUC[48-96h]</title>
        <description>Area under the P218-beta-acyl-glucuronide-OH plasma concentration-time curve from 48 hours after first P218 administration to 96 hours after first P218 administration</description>
        <time_frame>9 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P218 1000 mg - Cohort 1</title>
            <description>Two administrations of 1000 mg P218 (capsules p.o.), 48 hours apart&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: P218-beta-acyl-glucuronide-OH AUC[48-96h]</title>
          <description>Area under the P218-beta-acyl-glucuronide-OH plasma concentration-time curve from 48 hours after first P218 administration to 96 hours after first P218 administration</description>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27283" spread="7106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohorts 1, 2 and 3: P218 Cmax - Day 1</title>
        <description>Maximum observed P218 plasma concentration after each P218 administration</description>
        <time_frame>9 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P218 1000 mg (Oral Capsules) - Cohort 1</title>
            <description>Two administrations of 1000 mg P218 (capsules p.o.), 48 hours apart&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)</description>
          </group>
          <group group_id="O2">
            <title>P218 1000 mg (Oral Capsules) - Cohort 2</title>
            <description>One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
          <group group_id="O3">
            <title>P218 100 mg (Oral Capsules) - Cohort 3</title>
            <description>One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (100 mg) Oral Capsules: 100 mg P218 (2 x 50 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
        </group_list>
        <measure>
          <title>Cohorts 1, 2 and 3: P218 Cmax - Day 1</title>
          <description>Maximum observed P218 plasma concentration after each P218 administration</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7482" spread="3889"/>
                    <measurement group_id="O2" value="7241" spread="2983"/>
                    <measurement group_id="O3" value="856" spread="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohorts 1, 2 and 3: P218 Tmax - Day 1</title>
        <description>Time to P218 Cmax after each P218 administration</description>
        <time_frame>9 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P218 1000 mg (Oral Capsules) - Cohort 1</title>
            <description>Two administrations of 1000 mg P218 (capsules p.o.), 48 hours apart&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)</description>
          </group>
          <group group_id="O2">
            <title>P218 1000 mg (Oral Capsules) - Cohort 2</title>
            <description>One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
          <group group_id="O3">
            <title>P218 100 mg (Oral Capsules) - Cohort 3</title>
            <description>One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (100 mg) Oral Capsules: 100 mg P218 (2 x 50 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
          </group>
        </group_list>
        <measure>
          <title>Cohorts 1, 2 and 3: P218 Tmax - Day 1</title>
          <description>Time to P218 Cmax after each P218 administration</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.55" upper_limit="1.50"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.50" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from time of informed consent until the last study-related activity for each subject. A maximum period of 37 days for cohort 1, and 63 days for cohorts 2 and 3.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>P218 1000 mg - Cohort 1</title>
          <description>Two administrations of 1000 mg P218 (capsules p.o.), 48 hours apart&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)</description>
        </group>
        <group group_id="E2">
          <title>P218 Placebo - Cohort 1</title>
          <description>Two administrations of P218 placebo (capsules p.o.), 48 hours apart&#xD;
Placebo Oral Capsules: Placebo capsules matched to the P218 capsules with regard to appearance and taste</description>
        </group>
        <group group_id="E3">
          <title>P218 1000 mg - Challenge - Cohort 2</title>
          <description>One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (1000 mg) Oral Capsules: 1000 mg P218 (4 x 250 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
        </group>
        <group group_id="E4">
          <title>P218 100 mg - Challenge - Cohort 3</title>
          <description>One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.&#xD;
P218 (100 mg) Oral Capsules: 100 mg P218 (2 x 50 mg capsules)&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
        </group>
        <group group_id="E5">
          <title>P218 Placebo - Challenge - Cohorts 2 and 3</title>
          <description>One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.), 48 hours after first administration.&#xD;
Placebo Oral Capsules: Placebo capsules matched to the P218 capsules with regard to appearance and taste&#xD;
PfSPZ Challenge: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lip Dry</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Influenza-like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Joint Stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Slade</name_or_title>
      <organization>Medicines for Malaria Venture</organization>
      <phone>+41 22 555 0415</phone>
      <email>sladea@mmv.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

